Patients With SLE, HCQ-Related Retinal Toxicity Have Higher Prevalence Of Antiarrestin Antibodies Compared Against Those Without Toxicity, Study Finds
January 08, 2025
Rheumatology Advisor (1/7, Kuhns) reports, “Patients with systemic lupus erythematosus (SLE) and hydroxychloroquine (HCQ)-related retinal toxicity have a higher prevalence of antiretinal autoantibodies, particularly antiarrestin antibodies, compared against those without toxicity, according to study results.” The investigators said the research “suggests that anti-arrestin and” anti-PKM2 (pyruvate kinase M2) autoantibodies “may represent a potential new biomarker for risk of development of HCQ eye toxicity.” The findings were published in ACR Open Rheumatology.